Highlight
- The phase 3 POLARIX study showed Pola-R-CHP improves progression-free survival compared to R-CHOP in untreated diffuse large B-cell lymphoma (DLBCL).
- Patient-reported outcomes (PROs) reveal higher symptom incidence than clinician-reported adverse events (AEs), underscoring the need for patient-centric assessment tools.
- Both treatment arms demonstrated rapid and sustained improvements in health-related quality of life (HRQoL), particularly in global health status and lymphoma-related symptoms.
- Gastrointestinal symptoms were comparable between groups and returned to baseline after treatment, illustrating manageable symptom profiles.
Study Background
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, posing significant therapeutic challenges due to its heterogeneous clinical presentation and aggressive nature. Though combination chemoimmunotherapy regimens like R-CHOP have been the standard of care, relapse rates remain problematic, necessitating new therapeutic strategies that enhance efficacy while maintaining quality of life. Moreover, the symptomatic complexity of DLBCL—including systemic and lymphoma-related symptoms—can be exacerbated by treatment side effects, making evaluation of health-related quality of life (HRQoL) integral to comprehensive care assessment.
The phase 3 POLARIX trial investigates Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus standard R-CHOP in previously untreated DLBCL patients. Previous results from POLARIX established superior progression-free survival (PFS) with Pola-R-CHP and a comparable safety profile. This study focuses on integrating patient-reported outcomes (PROs) to more accurately characterize the patient experience, including symptom burden and HRQoL, complementing traditional clinician-reported adverse events (AEs).
Study Design
POLARIX (NCT03274492) is a randomized, multicenter, phase 3 trial enrolling adult patients with previously untreated DLBCL. Participants were randomized to receive Pola-R-CHP or R-CHOP, administered according to standard dosing schedules. The study evaluated efficacy through endpoints including progression-free survival and safety via clinician-reported adverse events.
For HRQoL assessment, validated PRO instruments captured changes from baseline in global health status/quality of life, lymphoma-specific symptoms, fatigue, role and emotional functioning, and gastrointestinal (GI) symptoms such as diarrhea, constipation, nausea, and vomiting. The PRO-evaluable population comprised 874 patients with baseline characteristics balanced across treatment arms. Comparative analyses examined the concordance and discrepancy between PRO-reported symptom incidence and clinician-reported AEs.
Key Findings
The POLARIX study reaffirmed Pola-R-CHP’s superior efficacy in improving progression-free survival relative to R-CHOP, with comparable safety profiles. Notably, the HRQoL data obtained through PROs provided nuanced insights into patient symptom burden and functional status throughout and following treatment.
1. Discordance Between PROs and Clinician-Reported AEs: Patients reported a consistently higher incidence and severity of symptoms, including fatigue and gastrointestinal complaints, compared with clinician documentation. This underlines the limitations of clinician-reported AEs as a solitary metric for tolerability and emphasizes the complementary role of PROs in capturing the full patient experience.
2. Quality of Life Improvements: Both treatment arms demonstrated rapid and sustained improvements in global health status and lymphoma symptoms, reflecting effective disease control and tolerability. Significant positive changes were observed in fatigue levels and various functional domains, including role, emotional, and social functioning, which are critical to patient well-being.
3. Gastrointestinal Symptom Profile: Incidences of diarrhea, constipation, nausea, and vomiting were similar between arms and, importantly, symptoms generally returned to baseline levels post-treatment. This suggests that Pola-R-CHP’s toxicity profile is manageable and does not impose additional long-term GI burden compared with R-CHOP.
4. Implications for Clinical Practice: Incorporating PRO data supports more patient-centered evaluations of new therapies, facilitating personalized symptom management and improved communication. The findings endorse Pola-R-CHP as an emerging standard with a patient-reported HRQoL benchmark in first-line DLBCL treatment.
Expert Commentary
The POLARIX trial exemplifies the evolving paradigm in oncology clinical trials toward integrating PRO assessments for a holistic appraisal of treatment impact. Recognized hematology experts highlight that while clinician-reported AEs remain crucial, patient-reported data provide indispensable granularity on symptom distress, functional impairment, and life quality changes that might otherwise be underestimated.
Limitations include the inherent subjectivity of PROs and potential reporting biases; however, standardized and validated instruments mitigate these concerns and enhance reliability. The generalizability of these findings is robust given the trial’s large sample size and diverse geographic representation.
Biologically, Polatuzumab vedotin’s targeted mechanism may contribute to preserving HRQoL by reducing off-target toxicities compared to vincristine-containing regimens. Further research integrating biomarker correlates of symptom burden could refine personalized therapy approaches.
Conclusion
The phase 3 POLARIX study advances the treatment landscape for previously untreated DLBCL by demonstrating Pola-R-CHP’s superiority in progression-free survival without compromising patient-reported quality of life. The notable discordance between patient-reported symptoms and clinician-reported adverse events underscores the imperative for integrating PRO instruments in clinical trials to comprehensively capture the patient experience.
These HRQoL findings reinforce Pola-R-CHP as a promising new standard of care, establishing a patient-centered benchmark in DLBCL management. Ongoing incorporation of PRO data into routine practice will enhance symptom monitoring, improve patient-clinician communication, and ultimately optimize therapeutic outcomes.
Funding and ClinicalTrials.gov
The POLARIX trial was funded and supported by the respective pharmaceutical sponsors of polatuzumab vedotin and associated agents. The study is registered at ClinicalTrials.gov under identifier NCT03274492.
References
Thompson C, Trněný M, Morschhauser F, et al. PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study. Blood. 2025 Sep 25:blood.2025028848. doi:10.1182/blood.2025028848. Epub ahead of print. PMID: 40997297.
Additional literature on PRO integration in oncology and DLBCL therapeutic advances supports the clinical significance of these findings.
